Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase NA 2Phase 3 2Phase 2/3 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 46Thoracic 34Breast 28Gynecologic 20Head & Neck 17Other hematologic neoplasm 13Lymphoid 13Genitourinary 9CNS 4Tumor-Agnostic 3Plasma cell 2Other solid neoplasm 2Dermatologic 2Sarcoma 1Myeloid 1

Conditions

Melanoma 2Neoplasms 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Drug Therapy × Dermatologic × Clear all
NCT02278887 2025-03-10

TIL

The Netherlands Cancer Institute

Phase 3 Completed
168 enrolled
Dermatologic

Melanoma

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

GlaxoSmithKline

Phase 3 Completed
322 enrolled 24 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡